Biotechnology & Life Sciences Global On demand · 24-48h

Global Genomics & Sequencing Automation Systems Market Strategic Research Report

Global Genomics & Sequencing Automation Systems Market Strat…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Genomics & Sequencing Automation Systems Market
$6.07B2025
6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Automated Liquid Handling Systems, Automated Nucleic Acid Extraction Systems, NGS Library Preparation Automation Systems, Robotic Sample Processing Workstations, Integrated Genomics Automation Platforms, Sequencing Workflow Automation Systems

By Application: Pharmaceutical and Biotechnology Companies, Clinical Diagnostic Laboratories, Academic and Research Institutes, Contract Research Organizations (CROs), Government and Public Health Laboratories, Population Genomics Centers

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Illumina, Thermo Fisher Scientific, Danaher, Agilent Technologies, Revvity, Roche Diagnostics, QIAGEN, Hamilton Company, Tecan, Becton Dickinson, Eppendorf, MGI Tech, BGI Genomics, Autobio Diagnostics, Haier Biomedical, DAAN Gene

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 130 pages
Market size 2025
$6.07B
Billion USD
Forecast CAGR
6%
2025-2032
Forecast 2032
$9.1B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Genomics & Sequencing Automation Systems market size is predicted to grow from US$ 6,065 million in 2025 to US$ 9,112 million in 2032; it is expected to grow at a CAGR of 6.0% from 2026 to 2032.

Genomics & Sequencing Automation Systems are integrated laboratory automation platforms designed to streamline, standardize, and accelerate genomic research and next-generation sequencing (NGS) workflows through the automated handling of biological samples, reagents, data processing, and sequencing preparation steps. These systems combine robotic liquid handling, nucleic acid extraction modules, sample tracking technologies, library preparation automation, laboratory information management systems (LIMS), and bioinformatics software to reduce manual intervention, improve reproducibility, increase throughput, and minimize human error.

Global key Genomics & Sequencing Automation Systems players cover Illumina, Thermo Fisher Scientific, Danaher, Agilent Technologies, Revvity, etc.

This report presents a comprehensive overview of the global Genomics & Sequencing Automation Systems market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Automated Liquid Handling Systems
  • Automated Nucleic Acid Extraction Systems
  • NGS Library Preparation Automation Systems
  • Robotic Sample Processing Workstations
  • Integrated Genomics Automation Platforms
  • Sequencing Workflow Automation Systems

Segment by Workflow Stage

  • Sample Accessioning and Tracking
  • DNA/RNA Extraction
  • Quantification and Quality Control
  • Library Preparation
  • Sample Normalization and Pooling
  • Sequencing Setup and Loading
  • Post-Sequencing Data Processing

Segment by Throughput Level

  • Low-Throughput Systems
  • Medium-Throughput Systems
  • High-Throughput Systems
  • Ultra-High-Throughput Genomics Platforms

Segment by Application

  • Pharmaceutical and Biotechnology Companies
  • Clinical Diagnostic Laboratories
  • Academic and Research Institutes
  • Contract Research Organizations (CROs)
  • Government and Public Health Laboratories
  • Population Genomics Centers

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Genomics & Sequencing Automation Systems market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmaceutical and Biotechnology Companies, Clinical Diagnostic Laboratories, Academic and Research Institutes evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Genomics & Sequencing Automation Systems Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$6.07B
2025
Forecast
$9.1B
2032
CAGR
6%
2025–2032
Regiones
5
global
Key companies
IlluminaThermo Fisher ScientificDanaherAgilent TechnologiesRevvityRoche DiagnosticsQIAGENHamilton Company
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Automated Liquid Handling SystemsAutomated Nucleic Acid Extraction SystemsNGS Library Preparation Automation SystemsRobotic Sample Processing WorkstationsIntegrated Genomics Automation PlatformsSequencing Workflow Automation Systems
By Application
Pharmaceutical and Biotechnology CompaniesClinical Diagnostic LaboratoriesAcademic and Research InstitutesContract Research Organizations (CROs)Government and Public Health LaboratoriesPopulation Genomics Centers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Automated Liquid Handling Systems
  • 3.1.3 Automated Nucleic Acid Extraction Systems
  • 3.1.4 NGS Library Preparation Automation Systems
  • 3.1.5 Robotic Sample Processing Workstations
  • 3.1.6 Integrated Genomics Automation Platforms
  • 3.1.7 Sequencing Workflow Automation Systems
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmaceutical and Biotechnology Companies
  • 4.1.3 Clinical Diagnostic Laboratories
  • 4.1.4 Academic and Research Institutes
  • 4.1.5 Contract Research Organizations (CROs)
  • 4.1.6 Government and Public Health Laboratories
  • 4.1.7 Population Genomics Centers
  • 4.1.8 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Illumina
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Danaher
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Agilent Technologies
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Revvity
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Roche Diagnostics
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 QIAGEN
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Hamilton Company
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Tecan
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Becton Dickinson
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Eppendorf
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 MGI Tech
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 BGI Genomics
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Autobio Diagnostics
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Haier Biomedical
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 DAAN Gene
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Genomics & Sequencing Automation Systems market size?
The global Genomics & Sequencing Automation Systems market is estimated at US$ 6.07 billion in 2025 (base year) and is projected to reach US$ 9.11 billion by 2032.
What growth rate is expected for the Genomics & Sequencing Automation Systems market through 2032?
The market is expected to grow at a CAGR of 6.0% from 2026 to 2032, expanding from US$ 6.07 billion in 2025 to US$ 9.11 billion in 2032, roughly 1.5 times its base-year value.
How is Genomics & Sequencing Automation Systems defined?
Genomics & Sequencing Automation Systems are integrated laboratory automation platforms designed to streamline, standardize, and accelerate genomic research and next-generation sequencing (NGS) workflows through the automated handling of biological samples, reagents, data processing, and sequencing preparation steps.
How is the Genomics & Sequencing Automation Systems market segmented by type?
By type, the market is segmented into Automated Liquid Handling Systems, Automated Nucleic Acid Extraction Systems, NGS Library Preparation Automation Systems, Robotic Sample Processing Workstations, Integrated Genomics Automation Platforms and Sequencing Workflow Automation Systems.
What are the key applications of Genomics & Sequencing Automation Systems?
Key applications covered include Pharmaceutical and Biotechnology Companies, Clinical Diagnostic Laboratories, Academic and Research Institutes, Contract Research Organizations (CROs), Government and Public Health Laboratories and Population Genomics Centers.
Which companies are profiled in the Genomics & Sequencing Automation Systems market report?
Key players profiled include Illumina, Thermo Fisher Scientific, Danaher, Agilent Technologies, Revvity, Roche Diagnostics, QIAGEN and Hamilton Company, among 16 companies covered in total.
What geographies does the Genomics & Sequencing Automation Systems market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Genomics & Sequencing Automation Systems market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmaceutical and Biotechnology Companies, Clinical Diagnostic Laboratories and Academic and Research Institutes, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Genomics & Sequencing Automation Systems market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.